Bayer Forecast, price target & analysts
Bayer Target price 2025 - Analyst rating & recommendation
Bayer Classifications & Recommendation:
Bayer Price Target
| Target Price | €26.89 |
| Price | €24.08 |
| Potential | 11.66% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target Bayer 2026 . The average Bayer target price is €26.89. This is 11.66% higher than the current stock price. The highest price target is €37.00 53.65% , the lowest is €22.00 8.64% . | |
| A rating was issued by 20 analysts: 5 Analysts recommend Bayer to buy, 15 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Bayer stock has an average upside potential 2026 of 11.66% . Most analysts recommend the Bayer stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2029
16 Analysts have issued a sales forecast Bayer 2025 . The average Bayer sales estimate is €46.4b . This is 0.39% lower than the revenue of the last 12 months(TTM). The highest sales forecast is €47.1b 1.00% , the lowest is €45.6b 2.07% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €46.6b | 2.16% |
|---|---|---|
| 2025 | €46.4b | 0.39% |
| 2026 | €47.2b | 1.63% |
| 2027 | €48.3b | 2.28% |
| 2028 | €49.2b | 1.89% |
| 2029 | €50.3b | 2.37% |
16 Analysts have issued an Bayer EBITDA forecast 2025. The average Bayer EBITDA estimate is €9.4b . This is 10.13% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €10.1b 17.50% , the lowest is €9.0b 4.75% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €8.5b | 30.89% |
|---|---|---|
| 2025 | €9.4b | 10.61% |
| 2026 | €9.9b | 4.62% |
| 2027 | €10.3b | 4.14% |
| 2028 | €10.3b | 0.48% |
| 2029 | €10.2b | 1.22% |
EBITDA Margin
| 2024 | 18.30% | 29.37% |
|---|---|---|
| 2025 | 20.32% | 11.04% |
| 2026 | 20.92% | 2.95% |
| 2027 | 21.30% | 1.82% |
| 2028 | 21.01% | 1.36% |
| 2029 | 20.27% | 3.52% |
10 Bayer Analysts have issued a net profit forecast 2025. The average Bayer net profit estimate is €2.1b . This is 182.66% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.6b 242.31% , the lowest is €1.3b 151.15% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | €-2.6b | 13.04% |
|---|---|---|
| 2025 | €2.1b | 182.66% |
| 2026 | €2.8b | 31.50% |
| 2027 | €3.2b | 14.32% |
| 2028 | €3.9b | 21.59% |
| 2029 | €4.2b | 8.47% |
Net Margin
| 2024 | -5.48% | 11.12% |
|---|---|---|
| 2025 | 4.55% | 183.02% |
| 2026 | 5.88% | 29.23% |
| 2027 | 6.58% | 11.90% |
| 2028 | 7.85% | 19.30% |
| 2029 | 8.32% | 5.99% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
10 Analysts have issued a Bayer forecast for earnings per share. The average Bayer EPS is €2.15 . This is 182.69% higher than earnings per share in the financial year 2024. The highest EPS forecast is €3.70 242.31% , the lowest is €1.33 151.15% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €-2.60 | 13.04% |
|---|---|---|
| 2025 | €2.15 | 182.69% |
| 2026 | €2.83 | 31.63% |
| 2027 | €3.23 | 14.13% |
| 2028 | €3.93 | 21.67% |
| 2029 | €4.26 | 8.40% |
P/E ratio
| Current | -9.27 | 5.82% |
|---|---|---|
| 2025 | 11.20 | 220.82% |
| 2026 | 8.52 | 23.93% |
| 2027 | 7.45 | 12.56% |
| 2028 | 6.13 | 17.72% |
| 2029 | 5.65 | 7.83% |
Based on analysts' sales estimates for 2025, the Bayer stock is valued at an EV/Sales of 1.22 and an P/S ratio of 0.51 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.21 | 3.97% |
|---|---|---|
| 2025 | 1.22 | 0.48% |
| 2026 | 1.20 | 1.60% |
| 2027 | 1.17 | 2.23% |
| 2028 | 1.15 | 1.86% |
| 2029 | 1.12 | 2.31% |
P/S ratio
| Current | 0.51 | 6.17% |
|---|---|---|
| 2025 | 0.51 | 0.39% |
| 2026 | 0.50 | 1.61% |
| 2027 | 0.49 | 2.23% |
| 2028 | 0.48 | 1.84% |
| 2029 | 0.47 | 2.33% |
Current Bayer Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| MWB RESEARCH AG |
Buy
➜
Buy
|
Unchanged | Jan 05 2025 |
| DZ BANK |
Buy
➜
Buy
|
Unchanged | Nov 28 2024 |
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Nov 25 2024 |
| HSBC |
Hold
➜
Hold
|
Unchanged | Nov 24 2024 |
| REDBURN ATLANTIC |
Neutral
➜
Neutral
|
Unchanged | Nov 19 2024 |
| BNP PARIBAS EXANE |
Outperform
➜
Outperform
|
Unchanged | Nov 18 2024 |
| STIFEL EUROPE |
Hold
➜
Hold
|
Unchanged | Nov 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
MWB RESEARCH AG:
Buy
➜
Buy
|
Jan 05 2025 |
|
Unchanged
DZ BANK:
Buy
➜
Buy
|
Nov 28 2024 |
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Nov 25 2024 |
|
Unchanged
HSBC:
Hold
➜
Hold
|
Nov 24 2024 |
|
Unchanged
REDBURN ATLANTIC:
Neutral
➜
Neutral
|
Nov 19 2024 |
|
Unchanged
BNP PARIBAS EXANE:
Outperform
➜
Outperform
|
Nov 18 2024 |
|
Unchanged
STIFEL EUROPE:
Hold
➜
Hold
|
Nov 18 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
